Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From LadRx Corporation
Global Top 10 Medtechs Swap Places After Latest Quarterlies
Abbott Laboratories moved above Medtronic in MAT medtech revenues, while Philips Healthcare and Stryker finished 2022 with strong quarters, and Roche dropped a few places.
Dealmaking Quarterly Statistics, Q4 2022
During Q4, biopharma merger and acquisition value reached $35.7bn and drew in $62.1bn in potential deal value from alliances. Device company M&A values reached $19.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.8bn.
Finance Watch: $1.32bn In New Biopharma VC Financings As Year-End Approaches
Private Company Edition: In recent weeks, 19 companies disclosed venture capital funding of $20m or more, including FogPharma with a $178m series D round and Apogee’s $169m launch. Also, Avalon BioVentures spun out of Avalon Ventures with a $135m fund.
Cordis Looks To Regain Previous Innovation Edge With Drug-Eluting Balloons
Medtech Insight followed-up with Cordis CEO Shar Matin to talk about the company’s path forward as an innovative intervention company following the acquisition of MedAlliance.
- Large Molecule
- Other Names / Subsidiaries
- Centurion BioPharma
- Innovive Pharmaceuticals
- Zynaxis Inc.
- CytRx Corp.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.